natgillin/translations-raw huggingface dataset:
The pharmacokinetics of RoActemra in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing ≥ 30 kg), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg), 162 
Farmakokinetiko zdravila RoActemra pri bolnikih s pJIA so ovrednotili s populacijsko farmakokinetično analizo, ki je vključevala 237 bolnikov; bolnike so zdravili z odmerkom 8 mg/kg intravensko vsake 4 tedne (bolniki s telesno maso ≥ 30 kg), odmerkom 10 mg/kg intravensko vsake 4 tedne (bolniki s telesno maso pod 30 kg), odmerkom 162 mg subkutano na 2 tedna (bolniki s telesno maso ≥ 30 kg) ali 162 mg subkutano vsake 3 tedne (bolniki s telesno maso pod 30 kg).
Duration (days) Mean (SD) 
Trajanje (dnevi)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE-FILLED SYRINGE CARTON 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA NAPOLNJEGA INJEKCIJSKEGA PERESNIKA
The recommended posology in patients above 2 years of age is 8 mg/kg once every 2 weeks in patients weighing greater than or equal to 30 kg or 12 mg/kg once every 2 weeks in patients weighing less than 30 kg. 
Priporočeno odmerjanje za bolnike, starejše od 2 let, je 8 mg/kg telesne mase enkrat na 2 tedna pri bolnikih, ki tehtajo 30 kg ali več in 12 mg/kg enkrat na 2 tedna pri bolnikih, ki tehtajo manj kot 30 kg. Odmerek je treba izračunati glede na bolnikovo telesno maso pred vsakim dajanjem.
Evaluable patients had been treated with tocilizumab 8 mg/kg (12 mg/kg for patients < 30 kg) with or without additional high-dose corticosteroids for severe or life-threatening CRS; only the first episode of CRS was included in the analysis. 
Ocenljive bolnike so zaradi hudega ali življenje ogrožajočega CRS zdravili s tocilizumabom v odmerku 8 mg/kg (bolnike s telesno maso < 30 kg z 12 mg/kg) z dodatkom velikih odmerkov kortikosteroidov ali brez njih.
During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials. 
V obdobju dvojno slepe kontrole ter pri dolgoročni izpostavljenosti sta vzorec in incidenca zmanjšanja števila nevtrofilcev ostala skladna s tem, kar so opazili v šestmesečnih kontroliranih kliničnih preskušanjih.
In the 6-month controlled trials decreases in platelet counts below 100 x 103/ μL occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 1% on placebo plus DMARDs. 
V šestmesečnih kontroliranih kliničnih preskušanjih se je število trombocitov zmanjšalo pod 100 x 103/µl pri 1,7 % bolnikov, ki so dobivali 8 mg/kg tocilizumaba v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili, in pri < 1 % tistih, ki so dobivali placebo v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili.
In RA, pJIA and sJIA patients, ALT/AST should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter. 
Pri bolnikih z revmatoidnim artritisom, pJIA in sJIA je treba vrednosti ALT in AST prvih 6 mesecev zdravljenja kontrolirati na 4 do 8 tednov, pozneje pa na 12 tednov.
Hepatic impairment: No formal study of the effect of hepatic impairment on the pharmacokinetics of RoActemra has been conducted. 
Okvara jeter: formalnih študij o vplivu okvare jeter na farmakokinetiko zdravila RoActemra niso izvedli.
• If the patient weighs 30 kg or more: the dose is 162 mg (the content of 1 pre-filled syringe) once every week 
• Če bolnik tehta 30 kg ali več: odmerek je 162 mg (vsebina ene napolnjene injekcijske brizge) enkrat na teden.
• Continue to keep the needle-shield pushed in. 
• zmanjšano delovanje žleze ščitnice.
Study II LITHE 
Študija II
The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 5.7 mL/h in paediatric patients with systemic juvenile idiopathic arthritis. 
Linearni očistek so ocenili kot parameter v analizi populacijske farmakokinetike in je pri pediatričnih bolnikih s sJIA znašal 5,7 ml/h.
During the double-blind controlled period and with long-term exposure, the pattern and incidence of elevation in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials. 
V obdobju dvojno slepe kontrole ter pri dolgoročni izpostavljenosti sta vzorec in incidenca zvišanja ALT/AST ostala skladna s tem, kar so opazili v šestmesečnih kontroliranih kliničnih preskušanjih.
• Pre-filled Syringe 
• napolnjena injekcijska brizga
STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 80 mg tocilizumab. 
1 viala vsebuje 80 mg tocilizumaba.
Predicted mean ± SD PK parameters at steady-state after subcutaneous dosing in GCA 
Predvideno povprečje ± std. odklon farmakokinetičnih (FK) parametrov v stanju dinamičnega ravnovesja po subkutani uporabi pri bolnikih z GCA
For subcutaneous administration, the effective t1/2 is up to 13 days for 162 mg every week and 5 days for 162 mg every other week in patients with RA at steady-state. 
Izločanje Za subkutano dajanje je pri bolnikih z revmatoidnim artritisom v stanju dinamičnega ravnovesja efektivni t1/2 do 13 dni za 162 mg vsak teden in 5 dni za 162 mg vsak drugi teden.
Doses of 8 mg/kg of tocilizumab were given every four weeks as monotherapy. 
bolnikov pa 8 mg/kg tocilizumaba v monoterapiji.
• Hold the needle-shield of the syringe firmly with one hand and pull off the needle-cap with the other hand. 
• Z eno roko trdno primite varovalo injekcijske igle, z drugo povlecite pokrovček injekcijske igle (glejte sliko D).
Statistically significant improvements in haemoglobin levels were observed with RoActemra compared with DMARDs (p< 0.0001) at week 24. 
Po 24 tednih so pri zdravilu RoActemra v primerjavi z imunomodulirajočimi antirevmatičnimi zdravili ugotovili statistično značilno izboljšanje koncentracije hemoglobina (p < 0,0001).
During routine laboratory monitoring in the RoActemra 12 month controlled clinical trial, elevation in 
Med rednim laboratorijskim spremljanjem v 12-mesečnem kontroliranem kliničnem preskušanju zdravila RoActemra se je pri 34 % bolnikov pojavilo trajno zvišanje celokupnega holesterola na
Pharmacodynamic effects 
Farmakokinetični parametri zdravila
In general, the ADRs in sJIA patients were similar in type to those seen in RA patients, see section 4.8. 
V splošnem so neželeni učinki pri bolnikih s sJIA podobnega tipa kot tisti, opaženi pri bolnikih z revmatoidnim artritisom (glejte poglavje 4.8).
Pre-filled Syringe parts 
Deli napolnjene injekcijske brizge
Doses of 4 or 8 mg/kg of RoActemraor placebo were given every four weeks as blinded therapy for 52 weeks in combination with stable MTX (10 mg to 25 mg weekly). 
Odmerke 4 ali 8 mg/kg zdravila RoActemra ali placebo so dobivali 52 tednov na štiri tedne kot terapijo z dvojno slepo kontrolo, v kombinaciji s stabilnim odmerkom metotreksata (od 10 do 25 mg na teden).
The decision to discontinue RoActemra in sJIA or pJIA for a laboratory abnormality should be based on the medical assessment of the individual patient. 
O ukinitvi zdravila RoActemra zaradi nenormalnih laboratorijskih vrednosti je treba pri sJIA ali pJIA presojati za vsakega bolnika posebej.
These may affect 1 in 10 patients or more 
Ti se lahko pojavijo pri več kot 1 od 10 bolnikov.
Figure H). 
6R).
RA, sJIA, pJIA and CRS Patients ≥ 30 kg 
Bolniki s sJIA, pJIA in CRS ≥ 30 kg
Each pack contains 4 pre-filled syringes with multipacks containing 12 (3 packs of 4) pre-filled syringes. 
Eno pakiranje vsebuje štiri napolnjene injekcijske brizge, skupno pakiranje vsebuje 12 (3 pakiranja po 4) napolnjenih injekcijskih brizg.
In the double-blind controlled studies 774 patients received RoActemra 4 mg/kg in combination with MTX, 1870 patients received tocilizumab 8 mg/kg in combination with MTX/other DMARDs and 288 patients received tocilizumab 8 mg/kg monotherapy. 
4 mg/kg tocilizumaba v kombinaciji z metotreksatom, 1.870 bolnikov 8 mg/kg tocilizumaba v kombinaciji z metotreksatom oz. drugimi imunomodulirajočimi antirevmatičnimi zdravili, 288
In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ L occurred in 3.4% of patients on RoActemra 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs. 
V šestmesečnih kontroliranih kliničnih preskušanjih se je število nevtrofilcev zmanjšalo pod 1 x 109/l pri 3,4 % bolnikov, ki so dobivali 8 mg/kg zdravila RoActemra v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili, in pri < 0,1 % bolnikov, ki so dobivali placebo v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili.
If the expiration date has passed, safely dispose of the pre-filled pen in a sharps container and get a new one. 
Napolnjeni injekcijski peresnik, ki mu je potekel rok uporabnosti, varno odstranite v zabojnik za ostre predmete in si priskrbite novega.
RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. 
Zdravilo RoActemra je indicirano za zdravljenje hudega ali življenje ogrožajočega sindroma sproščanja citokinov, ki ga sprožijo T-celice s himernim antigenskim receptorjem (Chimeric Antigen
• If the patient weighs less than 30 kg: the dose is 162 mg (the content of 1 pre-filled syringe), once every 3 weeks 
• Če bolnik tehta manj kot 30 kg: odmerek je 162 mg (vsebina ene napolnjene injekcijske brizge) enkrat na 3 tedne.
The assessment of the time to first GCA flare showed a significantly lower risk of flare for the RoActemra subcutaneous weekly group compared to placebo plus 26 weeks prednisone and placebo plus 52 weeks prednisone taper groups and for the RoActemra subcutaneous every other weekly group compared to placebo plus 26 weeks prednisone (when compared at a 0.01 significance level). 
tedenskim zmanjševanjem prednizona, ter v skupini, ki je prejemala zdravilo RoActemra subkutano vsak drugi teden, kot v skupini s placebom in 26-tedenskim zmanjševanjem prednizona (ob primerjavi na ravni značilnosti 0,01).
In the 6-month controlled trials decreases in neutrophil counts below 1 x 109/ l occurred in 3.4% of patients on tocilizumab 8 mg/kg plus DMARDs compared to < 0.1% of patients on placebo plus DMARDs. 
V šestmesečnih kontroliranih kliničnih preskušanjih se je število nevtrofilcev zmanjšalo pod 1 x 109/l pri 3,4 % bolnikov, ki so dobivali 8 mg/kg tocilizumaba v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili, in pri < 0,1 % bolnikov, ki so dobivali placebo v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili.
Respiratory, thoracic and mediastinal disorders 
Revmatoidni artritis in gigantocelični arteriitis
Doses of 4 or 8 mg/kg tocilizumab or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly). 
Odmerke 4 ali 8 mg/kg tocilizumaba ali placebo so dobivali na štiri tedne v kombinaciji s stabilnim odmerkom metotreksata (od 10 do 25 mg na teden).
Infusion related reactions pJIA1, sJIA2 
Splošne težave in spremembe na mestu aplikacije reakcije, povezane z infundiranjem pJIA 1, sJIA
In the double-blind controlled studies, 774 patients received tocilizumab 4 mg/kg in combination with MTX, 1870 patients received tocilizumab 8 mg/kg in combination with MTX or other DMARDs and 288 patients received tocilizumab 8 mg/kg monotherapy. 
V dvojno slepih, kontroliranih študijah je 774 bolnikov prejemalo 4 mg/kg tocilizumaba v kombinaciji z metotreksatom, 1870
The key secondary efficacy endpoint also based on the proportion of patients achieving sustained remission at week 52, comparing tocilizumab plus 26 weeks prednisone taper with placebo plus 52 weeks prednisone taper, was also met (Table 4). 
Primerjali so tocilizumab skupaj s 26-tedenskim zmanjševanjem prednizona ter placebo skupaj z 52-tedenskim zmanjševanjem prednizona (preglednica 4).
NAME OF THE MEDICINAL PRODUCT RoActemra 162 mg solution for injection in pre-filled syringe Tocilizumab 
Navodilo za uporabo RoActemra 162 mg raztopina za injiciranje v napolnjeni injekcijski brizgi tocilizumab
ALT ≥3 x ULN occurred in 3% of patients in the RoActemra subcutaneous weekly group compared to 2% in the placebo plus 52 week prednisone taper group and none in the placebo plus 26 week prednisone taper group. 
Zvišanje jetrnih transaminaz Med rednim laboratorijskim spremljanjem v 12-mesečnem kontroliranem kliničnem preskušanju se je zvišanje ALT na ≥ 3-kratno ZMN pojavilo pri 3 % bolnikov, ki so prejemali zdravilo RoActemra subkutano vsak teden, pri 2 % bolnikov, ki so prejemali placebo in prednizon z 52-tedenskim zmanjševanjem odmerka, ter pri nobenem od bolnikov, ki so prejemali placebo in prednizon s 26-tedenskim zmanjševanjem odmerka.
How to store RoActemra 
Shranjevanje zdravila RoActemra
Events of cholesterol increased were less frequently reported in the sJIA population than in the adult RA population. 
Neželeni učinek, o katerem pa so pri populaciji s sJIA poročali redkeje kot pri odrasli populaciji z revmatoidnim artritisom, je bil zvišan holesterol.
Very rare reports of pancytopenia have occurred in the post marketing setting. 
V obdobju po prihodu zdravila na trg so poročali o zelo redkih primerih pancitopenije.
• If the patient weighs 30 kg or more: the dose is 162 mg (the content of 1 pre-filled syringe), once every 2 weeks. 
• Če bolnik tehta 30 kg ali več: odmerek je 162 mg (vsebina ene napolnjene injekcijske brizge) enkrat na 2 tedna.
JIA ACR response rates at week 12 (% patients) 
Odziv JIA ACR po 12 tednih (% bolnikov) Odziv tocilizumab n = 75
If the pre-filled syringe is not used within 5 minutes of cap removal, you must dispose of it in a puncture resistant container and use a new pre-filled syringe. 
Če napolnjene injekcijske brizge ne uporabite v 5 minutah po odstranitvi pokrovčka, jo je treba zavreči v zabojnik za ostre predmete, odporen proti vbodom, in uporabiti novo.
In the 52-week open-label SC Study (WA28118), 23.4% and 35.4% of patients experienced a post baseline elevation of their LDL-cholesterol value to ≥130 mg/dL and total cholesterol value to ≥200 
V 52-tedenski odprti študiji s subkutano obliko (WA28118) je imelo v katerem koli času med študijskim zdravljenjem (ne v izhodišču) 23,4 % bolnikov zvišano vrednost holesterola LDL na
Mean (SD) * p<0.0001 ** p<0.005 (threshold for significance for primary and key secondary tests of superiority) ***Descriptive p value <0.005 ****Flare: recurrence of GCA signs or symptoms and/or ESR ≥30 mm/h - Increase in the prednisone dose required Remission: absence of flare and normalization of the CRP Sustained remission: remission from week 12 to week 52 -Patients must adhere to the protocol-defined prednisone taper ¹ analysis of the time (in days) between clinical remission and first disease flare 2 p-values are determined using a Van Elteren analysis for non-parametric data § statistical analyses has not been performed 
***p ≤ 0,0001; **p < 0,001; *p < 0,05; ‡ p-vrednost < 0,05 v primerjavi s placebom + MTX, a cilj je bil eksplorativen (ni bil vključen v hierarhijo statističnega testiranja, zato ga niso kontrolirali glede številčnosti)
Predicted mean ± SD PK parameters at steady-state after IV dosing in pJIA RoActemra PK Parameter 
Predvideno povprečje ± std. odklon farmakokinetičnih parametrov v stanju dinamičnega ravnovesja po intravenskem odmerjanju pri bolnikih s pJIA
All patients, especially children, should be up-to-date with all their vaccinations before they start treatment with RoActemra. 
Vsi bolniki, še posebno otroci, morajo pred začetkom zdravljenja z zdravilom
PARTICULARS TO APPEAR ON THE OUTER PACKAGING PRE-FILLED SYRINGE CARTON (WITH BLUE BOX) - Multipack 
ŠKATLA NAPOLNJENE INJEKCIJSKEGA PERESNIKA (S PODATKI MODREGA OKENCA) - skupno pakiranje
JIA ACR30 Response 
JIA ACR 30 nenadno poslabšanje
Immune system disorders 
Bolezni imunskega sistema anafilaksija
• If the patient weighs less than 30 kg: the dose is 162 mg (the content of 1 pre-filled syringe) once every 2 weeks 
• Če bolnik tehta manj kot 30 kg: odmerek je 162 mg (vsebina ene napolnjene injekcijske brizge) enkrat na 2 tedna.
During the withdrawal phase (Part II), the percentage of patients achieving JIA ACR 30, 50, and 70 responses at Week 40 relative to baseline are shown in Table 8. 
del) po 40 tednih dosegli odzive JIA ACR 30, 50 in 70 glede na izhodiščno vrednost.
If a patient misses a subcutaneous weekly injection of RoActemra within 7 days of the scheduled dose, he/she should be instructed to take the missed dose on the next scheduled day. 
Če je od izpuščenega tedenskega odmerka subkutane injekcije zdravila RoActemra pri bolniku s sJIA minilo manj kot 7 dni, je treba bolniku naročiti, da izpuščeni odmerek vzame na dan naslednjega načrtovanega odmerka.
The proportion of patients with serious adverse events was balanced between the treatment groups (RoActemra 11.7% vs. adalimumab 9.9%). 
(zdravilo RoActemra 11,7 % v primerjavi z adalimumabom 9,9 %).
Dose interruptions of tocilizumab for the following laboratory abnormalities are recommended in pJIA patients in the tables below. 
V primeru nenormalnih laboratorijskih vrednosti je pri bolnikih s pJIA priporočljivo uporabo tocilizumaba prekiniti, kot je opisano v spodnjih preglednicah.
The pharmacokinetics of RoActemra were determined using a population pharmacokinetic analysis on a database composed of 3552 RA patients treated with a one-hour infusion of 4 or 8 mg/kg RoActemra every 4 weeks for 24 weeks or with 162 mg RoActemra given subcutaneously either once a week or every other week for 24 weeks. 
3552 bolnikov z revmatoidnim artritisom, ki so 24 tednov na 4 tedne dobivali enourno infuzijo 4 ali 8 mg/kg zdravila RoActemra, ali 24 tednov 162 mg zdravila RoActemra subkutano bodisi enkrat tedensko ali vsak drugi teden.
Malignancies 
Nevtrofilci
Hrvatska 
urtikarija
During routine laboratory monitoring in the intravenous RoActemra study WA19977 3.4% and 10.4% of patients experienced a post-baseline elevation of their LDL-cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL at any time during the study treatment, respectively. 
Vrednosti lipidov V študiji s subkutano obliko je imelo v katerem koli času med študijskim zdravljenjem (ne v izhodišču) 14,3 % bolnikov zvišano vrednost holesterola LDL na ≥ 130 mg/dl in 12,8 % bolnikov zvišano vrednost celokupnega holesterola na ≥ 200 mg/dl.
sJIA Patients 
Pri štirih bolnikih
Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks in combination with stable MTX (10 mg to 25 mg weekly). 
Odmerke 4 ali 8 mg/kg zdravila RoActemra ali placebo so dobivali na štiri tedne v kombinaciji s stabilnim odmerkom metotreksata (od 10 do 25 mg na teden).
Before you use RoActemra, your doctor may do a blood test to measure your liver function. 
Zdravnik lahko opravi preiskave krvi, da preveri jetrno delovanje, preden boste dobili zdravilo RoActemra.
For the 162 mg every week dose, the predicted mean (±SD) steady-state AUC1week, Cmin and Cmax of RoActemra were 
Za odmerek 162 mg vsak drugi teden je bila pričakovana povprečna (± SD) površina pod krivuljo
Pack sizes of 4 pre-filled syringes and multipacks containing 12 (3 packs of 4) pre-filled syringes. 
Na voljo je pakiranje s 4 napolnjenimi injekcijskimi brizgami in skupno pakiranje, ki vsebuje 12 (3 pakiranja po 4) napolnjenih injekcijskih brizg.
In the RoActemra subcutaneous weekly group, one patient (1.1%, 1/95) developed positive neutralizing anti-RoActemra antibodies, though not of the IgE isotype. 
1/95) pojavila pozitivna nevtralizirajoča protitelesa proti zdravilu RoActemra, ki pa niso bila izotipa IgE.
Of the 46 patients (1.6%) who developed anti-RoActemra antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment. 
jih je 6 imelo spremljajočo klinično pomembno preobčutljivostno reakcijo, ki je v 5 primerih vodila v ukinitev zdravljenja.
During routine laboratory monitoring in the RoActemra 6 month controlled clinical trial SC-I, 19% of patients experienced sustained elevations in total cholesterol > 6.2 mmol/L (240 mg/dl), with 9% experiencing a sustained increase in LDL to ≥ 4.1 mmol/L(160 mg/dL) on the subcutaneous weekly dose. 
Vrednosti lipidov V okviru rutinskega laboratorijskega spremljanja v šestmesečnem kontroliranem kliničnem preskušanju zdravila RoActemra SC-I se je pri 19 % bolnikov, ki so prejemali subkutani tedenski odmerek, pojavilo dolgotrajno zvišanje celotnega holesterola na > 6,2 mmol/l (240 mg/dl), pri 9 %
Exploratory efficacy results showed that RoActemra SC improved all exploratory efficacy parameters including Juvenile Arthritis Disease Activity Score (JADAS)-71, for TCZ naïve patients and maintained all exploratory efficacy parameters for patients who switched from RoActemra IV to RoActemra SC treatment over the entire course of the study for patients in both body weight groups 
Eksploratorni rezultati učinkovitosti so pokazali, da je zdravilo RoActemra v subkutani obliki izboljšalo vse eksploratorne parametre učinkovitosti, vključno z indeksom za juvenilni artritis
The pharmacokinetics of tocilizumab in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 
Farmakokinetiko tocilizumaba so proučili s populacijsko farmakokinetično analizo podatkov 3552
During the double-blind controlled period and with long-term exposure, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials. 
V obdobju dvojno slepe kontrole ter pri dolgoročni izpostavljenosti sta vzorec in incidenca zmanjšanja števila trombocitov ostala skladna s tem, kar so opazili v šestmesečnih kontroliranih kliničnih preskušanjih.
Similarly the proportion of patients achieving a DAS 28 remission (DAS28 < 2.6) was significantly higher (31% vs. 16% respectively) in patients receiving RoActemra 8 mg/kg plus DMARD than in patients receiving RoActemra 4 mg/kg plus DMARD (p< 0.0001). 
(DAS28 < 2,6) značilno večji delež bolnikov, ki so dobivali 8 mg/kg zdravila RoActemra skupaj z imunomodulirajočimi antirevmatičnimi zdravili, kot bolnikov, ki so dobivali 4 mg/kg zdravila RoActemra skupaj z imunomodulirajočimi antirevmatičnimi zdravili (31 % v prim.
Significant reduction in DAS28 from baseline (mean improvement) of 3.1-3.4 were observed in tocilizumab-treated patients compared to control patients (1.3-2.1). 
Pri bolnikih, zdravljenih s tocilizumabom, so ugotovili značilno znižanje (povprečno izboljšanje) DAS28 za 3,1 do 3,4 od izhodišča v primerjavi s kontrolnimi bolniki
Tell your doctor immediately if you feel unwell. 
Če se ne počutite dobro, morate to nemudoma povedati zdravniku.
Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in sJIA patients. 
Zmanjšanja odmerka tocilizumaba zaradi nenormalnih laboratorijskih vrednosti pri bolnikih s sJIA
Elevations of ALT/AST > 5 x ULN were observed in 0.7% of tocilizumab monotherapy patients and 1.4% of tocilizumab plus DMARD patients, the majority of whom were discontinued permanently from tocilizumab treatment. 
bolnikov, ki so dobivali tocilizumab v monoterapiji, in pri 1,4 % bolnikov, ki so tocilizumab dobivali v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili; pri večini teh so zdravljenje s tocilizumabom ukinili.
Keep the pre-filled syringes in the outer carton in order to protect from light and moisture. 
Napolnjene injekcijske peresnike shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo in vlago.
• Patient Information Pack 
• izobraževalno gradivo za bolnike.
Skin and subcutaneous tissue disorders 
prsnega koša in mediastinalnega prostora kašelj, dispneja
Because RoActemra is given in one pre-filled syringe, it is unlikely that you will receive too much. 
Če ste uporabili večji odmerek zdravila RoActemra, kot bi smeli Ker je zdravilo RoActemra pripravljeno v eni napolnjeni injekcijski brizgi, ni verjetno, da bi uporabili prevelik odmerek.
Leukopenia, Neutropenia, Hypofibrinogenae mia 
Bolezni živčevja glavobol, omotica
Doses of 4 or 8 mg/kg RoActemra or placebo were given every four weeks, in combination with stable MTX (10 mg to 25 mg weekly). 
8 mg/kg zdravila RoActemra ali placebo so dobivali na štiri tedne v kombinaciji s stabilnim odmerkom metotreksata (od 10 do 25 mg na teden).